Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE AR101 Follow-on Study
2016-004941-94Phase 3Completed
- Sponsor
- Aimmune Therapeutics, Inc.
- Start
- Feb 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peanut protein in peanut allergy, sponsored by Aimmune Therapeutics, Inc. Primary endpoint: Treatment-related adverse events. Started Feb 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2016-004941-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004941-94.